加载中
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
前收盘价
US$4.08
−US$0.39 · -8.72%
盘后
US$4.12
+US$0.04 · +0.98%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
日内区间
当前US$4.08
52周区间
当前US$4.08
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
26
偏贵
情绪
54
多空交织
风险
82
极高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
日内区间
当前US$4.08
52周区间
当前US$4.08
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 85.6万 USD | 130.6万 USD | 287.9万 USD | 134.7万 USD | 106.9万 USD |
| 销货成本 | 22.5万 USD | 80万 USD | 68.3万 USD | 32.2万 USD | 3.3万 USD |
| 毛利 | 63.1万 USD | 50.6万 USD | 219.6万 USD | 102.5万 USD | 103.6万 USD |
| 研究与开发 | 218.6万 USD | 181.5万 USD | 164.1万 USD | 280.3万 USD | 199万 USD |
| 销售、一般及管理费用 | 543.8万 USD | 580.5万 USD | 613.2万 USD | 626.8万 USD | 364.3万 USD |
| 营业费用 | 938万 USD | 782.2万 USD | 796.9万 USD | 840.5万 USD | 576.8万 USD |
| 利息收入 | 20.7万 USD | 42.1万 USD | — | 124万 USD | 1.8万 USD |
| 利息支出 | 1.1万 USD | 3万 USD | 9000 USD | 3.6万 USD | 1.2万 USD |
| 折旧和摊销 | 23.4万 USD | 48.2万 USD | 53.8万 USD | 18.7万 USD | 3.3万 USD |
| 营业利润 | −874.9万 USD | −731.6万 USD | −577.3万 USD | −738万 USD | −576.8万 USD |
| 净利润 | −1217.9万 USD | −628.4万 USD | −512.2万 USD | −259.2万 USD | −580.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年3月4日 | 1:9 | — | — |
股票拆分 | 2025年7月3日 | 1:21 | — | — |
股票拆分 | 2023年9月28日 | 1:26 | — | — |
已生效 2026年3月4日
1:9
已生效 2025年7月3日
1:21
已生效 2023年9月28日
1:26
报告持有此股票敞口的交易所交易基金。
Avantis Emerging Markets Equity ETFAVEM128.51万—284.09亿 USD0.33%US$93.27-0.89%
Avantis Emerging Markets Value ETFAVES21.56万0.01%15.67亿 USD0.36%US$65.31-0.38%
Avantis Emerging Markets Small Cap Equity ETFAVEE12.66万0.09%1.4亿 USD0.42%US$69.57-0.46%
Avantis Emerging Markets ex-China Equity ETFAVXC12.32万0.03%4.69亿 USD0.33%US$81.4556-0.85%Avantis Emerging Markets Equity ETFAVEMAvantis Emerging Markets Value ETFAVESAvantis Emerging Markets Small Cap Equity ETFAVEEAvantis Emerging Markets ex-China Equity ETFAVXCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
